The peptide commonly referred to as BPC-157 is a synthetic 15-amino-acid sequence corresponding to a fragment of a larger protein isolated from human gastric juice in the early 1990s. Since its characterization by Sikiric and colleagues, a substantial preclinical literature has accumulated across rodent models of tendon, ligament, muscle, gastrointestinal, and vascular tissue repair. This review does not make therapeutic claims — it collates what the published research has investigated and names the open questions a careful reader might take to the bench.
Origin and naming
The parent protein is referred to in the older literature as 'body protection compound' — a gastric juice fraction with cytoprotective activity in experimental ulcer models. The 15-residue sequence GEPPPGKPADDAGLV was identified as a stable fragment retaining much of the biological activity observed with the parent preparation. The pentadecapeptide is frequently written as 'PL-14736' or 'BPC 157' in the primary literature.
What the literature has investigated
Three clusters of preclinical research dominate the corpus. The first concerns gastrointestinal models — in rodents, BPC-157 has been examined in studies of gastric ulcer healing, colitis, and post-surgical anastomotic integrity. The second concerns musculoskeletal repair — Achilles tendon transection, medial collateral ligament injury, and crush-injury muscle models have all been published. The third concerns vascular and cytoprotective signaling — VEGFR2 internalization, nitric oxide system modulation, and collateral vessel formation in vascular occlusion models.
What makes BPC-157 methodologically interesting is not a single headline result — it is the breadth of model systems in which a consistent repair phenotype has been reported.
Open methodological questions
Several questions remain active. Pharmacokinetic data in plasma is limited relative to the volume of pharmacodynamic reports. The mechanism of action is described in terms of several converging signaling pathways, but a unifying model has not been established. Clinical trial data is sparse. Researchers interested in this peptide should read the primary literature directly and treat any tertiary summary — including this one — as an entry point, not an endpoint.
Further reading
- Sikiric P, et al. Current Pharmaceutical Design (2011). PMID: 21443483
- Sikiric P, et al. Current Neuropharmacology (2016). PMID: 27829933
- Staresinic M, et al. Journal of Orthopaedic Research (2003). PMID: 14554207
- Chang CH, et al. Journal of Applied Physiology (2011). PMID: 21030672
- Sikiric P, et al. Neural Regeneration Research (2022). PMID: 34472452